NEW YORK (GenomeWeb News) – The UK government has invested £12.8 million ($20.4 million) to build a new facility that will house the Manchester Cancer Research Centre (MCRC), a research partnership between the University of Manchester, The Christie NHS Foundation Trust, and Cancer Research UK, according to the University.
The new funding will cover part of the costs of the £38 million, multi-partner project, which will be located in Withington and will be home to a range of collaborative research projects aimed at translating lab discoveries into personalized cancer medicine. It also will help fund the purchase of specialized equipment.
The award, announced late last week, was provided by the Higher Education Funding Council for England (HEFCE) under the UK Research Partnership Investment Fund (UKRPIF).
The research at the MCRC will focus on using studies of tumor biology to inform development of new cancer treatments and will include basic lab research, clinical trials, and patient care in five areas, including radiation therapy, lung cancer, women’s cancers, melanoma, and hematological oncology.
The MCRC already is engaged in a wide array of cancer research projects, many of which use 'omics-based approaches to study cancer biology, prevention, risk assessment, and new treatments.
Among its many research groups are the Breast Cancer Risk and Detection Group, which is studying more than 800 families with BRCA1/2 mutations to develop new ways to predict the risk associated with these mutations, and the Molecular Cancer Group, which is engaged in a number of research approaches, including genetic analysis, aimed understanding relationships between gene expression, cell cycle, and tumor development.
The MCRC bid for UKRPIF funding was made possible with additional funding from a range of businesses, charities, and philanthropists, including AstraZeneca, the Wolfson Foundation, and the Oglesby Charitable Trust.